Illlumina said Tuesday that it has acquired data analysis firm Edico Genome.
Edico markets its DRAGEN platform, which uses field programmable gate array technology in combination with proprietary software algorithms to reduce data footprint and enable faster speeds. Users can run DRAGEN on site, in the cloud or in a hybrid mode, and can use a variety of different cloud storage solutions and analysis pipelines.
“Our acquisition of Edico Genome is a big step toward realizing the vision of reducing sequencing data acquisition and analysis to a push-button, standardized process,” Susan Tousi, senior vice president of product development at Illumina, said in a statement.
Edico President and CEO Pieter van Rooyen added, “As the scale of sequencing expands, decreasing the cost and time of analysis will be important to fuel the clinical adoption of sequencing.”
Stephen Kingsmore’s group at Rady Children’s Institute for Genomic Medicine has been using Edico’s DRAGEN to speed up the time-to-diagnosis for its whole-genome sequencing pipeline for critically ill infants in the NICU and has developed a rapid protocol that take just under 24 hours.
Financial details of the acquisition were not disclosed.
The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.
Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.
Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.